BlackRock Investment Management’s Atara Biotherapeutics ATRA Stock Holding History

BlackRock Investment Management’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$1.32M	Sell	3,717 -37	-1%	-$15.7K	﹤0.01%	2507
2016 Q3	$2.01M	Sell	3,754 -14	-0.4%	-$7.6K	﹤0.01%	2158
2016 Q2	$2.12M	Buy	3,768 +1,502	+66%	+$721K	﹤0.01%	2050
2016 Q1	$1.08M	Buy	2,266 +26	+1%	+$11.7K	﹤0.01%	2434
2015 Q4	$1.48M	Sell	2,240 -97	-4%	-$73.4K	﹤0.01%	2296
2015 Q3	$1.84M	Buy	2,337 +383	+20%	+$467K	﹤0.01%	2136
2015 Q2	$2.58M	Buy	1,954 +1,140	+140%	+$1.31M	﹤0.01%	2024
2015 Q1	$846K	Buy	814 +166	+26%	+$110K	﹤0.01%	2630
2014 Q4	$433K	Buy	+648	New	+$396K	﹤0.01%	3072

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock Investment Management's ATRA Position: Q4 2016 in Review

BlackRock Investment Management reduced its Atara Biotherapeutics (ATRA) stake by 0.99% in Q4 2016, selling an estimated $15.7K and leaving 3,717 shares worth $1.32M. The position accounts for ﹤0.01% of the portfolio, ranked #2507.

BlackRock Investment Management first reported a position in ATRA in Q4 2014 and has held it in 9 quarters since. The position peaked at $2.58M in Q2 2015. 85 funds tracked by Wall St. Rank hold ATRA as of Q4 2016.

BlackRock Investment Management held 3,717 shares of Atara Biotherapeutics worth $1.32M as of Q4 2016.
BlackRock Investment Management sold 37 Atara Biotherapeutics shares in Q4 2016, an estimated $15.7K.
Atara Biotherapeutics made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #2507 holding.
BlackRock Investment Management first reported a position in Atara Biotherapeutics in Q4 2014 and has held it in 9 quarters since.
BlackRock Investment Management's Atara Biotherapeutics position peaked at $2.58M in Q2 2015.
85 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.